Back to top
more

Encompass Health (EHC)

(Delayed Data from NYSE)

$84.49 USD

84.49
408,899

-0.06 (-0.07%)

Updated May 24, 2024 04:00 PM ET

After-Market: $84.46 -0.03 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Change Healthcare (CHNG) Stock

by Zacks Equity Research

Change Healthcare (CHNG) continues to benefit from robust payment accuracy business. However, intense competition remains a woe.

Patterson Companies' (PDCO) Unit Completes Miller Vet Buyout

by Zacks Equity Research

Patterson Companies' (PDCO) subsidiary completes acquisition of Miller Vet, which is likely to bolster its Animal Health's presence in the companion animal market.

Encompass Health (EHC) Expands Inpatient Rehab Business

by Zacks Equity Research

Encompass Health (EHC) continues to strengthen its inpatient rehabilitation business by opening a hospital.

Ecolab (ECL) to Aid Life Sciences Industry With New Offering

by Zacks Equity Research

Ecolab (ECL) unveils new virtual service offering to help the life sciences industry to address cleaning and disinfection challenges.

Here's Why You Should Invest in Intuitive Surgical (ISRG) Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vince Surgical System.

DaVita's (DVA) Deal to Aid Patients in Kidney Transplantation

by Zacks Equity Research

DaVita (DVA) and NKF collaborate to help kidney patients seeking a living donor, thereby improving health equity in kidney transplant process.

Cardinal Health's (CAH) Arm Receives FDA Nod for LYMPHOSEEK

by Zacks Equity Research

Cardinal Health's (CAH) Nuclear & Precision Health Solutions receive FDA approval for LYMPHOSEEK injection.

BD's (BDX) Milestone Pandemic Orders to Support Vaccinations

by Zacks Equity Research

BD (BDX) receives 2 billion pandemic orders for needles and syringes to support global COVID-19 vaccination efforts.

Here's Why You Should Retain AmerisourceBergen (ABC) Now

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment.

AngioDynamics (ANGO) Receives FDA Nod for AlphaVac System

by Zacks Equity Research

AngioDynamics (ANGO) gets 510(k) clearance from the FDA for the AlphaVac System for the non-surgical removal of thrombi or emboli from the vasculature.

DENTSPLY SIRONA (XRAY) Boosts Clear Aligner Foothold With Buyout

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) to fortifies its presence further in the clear aligner market with the acquisition of Propel Orthodontics.

Encompass Health (EHC) Buys Frontier, Boosts Home Health Services

by Zacks Equity Research

Encompass Health (EHC) completes the purchase of Frontier, which reflects its efforts to offer enhanced care across several states.

Why Is Encompass Health (EHC) Up 0.3% Since Last Earnings Report?

by Zacks Equity Research

Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Encompass Health (EHC) Gains on Strong Revenues & Cash Flows

by Zacks Equity Research

Encompass Health (EHC) set to benefit on the back of consistent top-line growth, robust 2021 business outlook and strong liquidity stand.

Canopy Growth (CGC) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Continued robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal fourth quarter.

EHC or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EHC vs. CHE: Which Stock Is the Better Value Option?

What's in Store for Intersect ENT's (XENT) Q1 Earnings?

by Zacks Equity Research

PROPEL and SINUVA are expected to have contributed to Intersect ENT's (XENT) first-quarter revenues.

Zacks.com featured highlights include: Encompass Health, Facebook, MKS Instruments, Blackstone Group and Interpublic Group of Companies

by Zacks Equity Research

Zacks.com featured highlights include: Encompass Health, Facebook, MKS Instruments, Blackstone Group and Interpublic Group of Companies

Swayta Shah headshot

Robust Sales Growth Make These 5 Stocks Worth Betting on Now

by Swayta Shah

Strong sales growth is one of the most important characteristics of potential winners in the stock market. Let's check out Encompass Health (EHC), Facebook (FB), MKS Instruments (MKSI), Blackstone (BX) and Interpublic Group (IPG) that may record solid sales growth.

Urmimala Biswas headshot

7 Great Value Picks Based on Discounted PEG

by Urmimala Biswas

Here are seven out of the 50 stocks that qualify the screening.

EHC or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EHC vs. CHE: Which Stock Is the Better Value Option?

Encompass Health (EHC) Q1 Earnings Beat, Hikes '21 View

by Zacks Equity Research

Encompass Health's (EHC) first-quarter results reflect improved Inpatient Rehabilitation segment revenues, partly offset by lower volumes in both its segments and higher costs.

Encompass Health (EHC) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Encompass Health (EHC) delivered earnings and revenue surprises of 31.25% and 0.15%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Encompass Health (EHC) Takes Nationwide Hospital Count to 139

by Zacks Equity Research

Encompass Health (EHC) opens an inpatient rehabilitation hospital in Florida, which highlights its efforts to offer enhanced rehabilitative care in the state.

Encompass Health (EHC) Opens Hospital, Boosts Texas Presence

by Zacks Equity Research

Encompass Health (EHC) opens an inpatient rehabilitation hospital in Texas, which reinforces the company's efforts to broaden presence in the state.